Skip to Main Content
Contribute Try STAT+ Today

As breakthrough drugs stream out of biopharmaceutical laboratories, how much they should cost and who will get access to them remain thorny issues.

During his campaign for president, Joe Biden indicated that he plans to set reimbursement for specialty biologic drugs through value assessments conducted by a single independent review board, which could prove to be a problem for patients and vulnerable citizens. Review boards conducting similar value assessments can be rife with conflicts of interests and lean on methodologies that disadvantage certain drugs and the patients who may desperately need them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The idea that patients always benefit from rapid access to any new drug is a favourite industry talking point, but the only clear-cut beneficiary of this kind of no-holds-barred access is industry itself.

    For example, many new drugs provide only marginal benefits over existing treatments even according to data from pivotal clinical trials (which tend to overstate efficacy):

    At the same time, these new drugs’ harm profiles are poorly understood, putting patients at risk. Overall, HTAs in Europe are doing a great job of protecting patients from drugs that are neither worth taking nor worth paying for.

    It would be nice if STAT had insisted on a bit more nuance in this contribution.

Comments are closed.